GANX

Gain Therapeutics, Inc. (GANX) | Rumor.io

Gain Therapeutics

GANX

Attention (50-day avg)0.01%

Attention rank (50-day avg)#586

Bullish sentiment (50-day avg)86%

Price to earnings ratio-2.9

Market capitalization77.2M

Earnings per share-0.5

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)-20.2M

Social

What share of all stock conversation is about GANX?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0.04% +0.02	0.01% +0	0.01% 0	0.01% +0

Sep 29

The CFO of Gain Therapeutics, Inc. (GANX) is leaving the company, and his departure may be seen as a non-material change that could lead to a buying opportunity.
The company's Phase 2 study is expected to begin immediately, and some investors are optimistic about the potential for a "pretty healthy bounce back" in the stock price by the end of the week.
The CFO's departure may be related to an impending business partnership (BP) deal, which could have implications for the company's financial management and SEC filings.

Generated by AI

Sentiment

Of the messages about GANX that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	73.38% -10.23	79.32% -13.87	85.76% -0.63	88.02% -7.5
Bearish	26.62% +10.23	20.68% +13.87	14.24% +0.63	11.98% +7.5

Bullish· Sep 29

The recent change in executive team is considered non-material, and the company is expected to begin its Phase 2 study immediately, providing a catalyst for the stock.
The buying activity in ITM calls, with over 1,200 $2 calls purchased while others are panicking, suggests a strong sentiment among investors.
The stock has the potential to close in the green, and some investors are confident that the share price will recover, with one predicting a "dip then rip" scenario.

Bearish· Sep 29

The company's CFO and CMO may be leaving, which could negatively impact the company's performance.
The stock's price has collapsed after a significant number of calls were traded, indicating a lack of confidence in the company's prospects.
The company's management may be incompetent, with one user suggesting that the company's demise is likely due to poor leadership.

Generated by AI

Topics

Of the messages about GANX that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	100%	66.67%	72.78%	51.07%
Technical Analysis	0%	31.67%	24.05%	27.58%
Analysts	0%	0%	2.53%	16.81%
Earnings	0%	1.67%	0.63%	3.37%
Macro	0%	0%	0%	0.33%
Controversies	0%	0%	0%	0.84%

Jun 29

Gain Therapeutics, Inc. (GANX) received FDA clearance to advance GT-02287 into Phase 2 clinical development for Parkinson's disease.
The IND authorization clears the path for Phase 2 clinical development in the U.S., expected to begin in 3Q26.
Phase 1 data showed favorable safety and tolerability, and biomarker and clinical evidence of activity for GT-02287 in both healthy volunteers and people with Parkinson's disease.

Generated by AI

Community

Of the messages about GANX, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	86.23%	90.21%	92.47%	61.38%
Newcomers	13.77%	9.79%	7.53%	38.62%

Regulars· Sep 29

The market's reaction to the CFO's departure seems to be a mix of disappointment and opportunity, with some traders seeing it as a "head-fake" that could lead to a rally.
The potential start of Phase 2 clinical trials, either with or without a partner, is a topic of discussion, with some speculating that the market may react negatively again if the news is not presented transparently.
The company's pipeline of disease-modifying therapies, including a potential treatment for Parkinson's disease, is seen as a major advantage over competitors like Abbvie, with some traders speculating that the stock could be renamed in the future due to the potential for significant profits.

Newcomers· Feb 24

Newcomers are optimistic about Gain Therapeutics' GT-02287's potential to modify Parkinson's disease.
GT-02287's disease-modifying effects are a key focus for these newcomers, with some seeing it as a game-changer.
Some newcomers are holding onto GANX, expecting a continued upward trend based on GT-02287's potential.

Generated by AI

News

Gain Therapeutics announces CFO resignation and interim appointment

1d agoInvesting.com

Gain Therapeutics to Participate at ROTH Fifth Annual Healthcare Opportunities Conference

13d agoYahoo Finance

H.C. Wainwright reiterates Gain Therapeutics stock rating at buy

29d agoInvesting.com

Gain Therapeutics to Participate at H.C. Wainwright 28th Annual Global Investment Conference

BETHESDA, Md., Aug. 25, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain” or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced that Gene Mack, President and CEO, will participate in one-on-one meetings at the H.C. Wainwright 28th Annual Global Investment Conference, held September 14-16 in New York City, NY. On-demand Company Presentation Date and Time:

1mo agoYahoo Finance

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Gain Therapeutics (GANX), Summit Therapeutics (SMMT) and Elutia (ELUT)

Detailed price information for Summit Therapeu ADR (SMMT-Q) from The Globe and Mail including charting and trades.

1mo agoThe Globe and Mail

Gain Therapeutics (GANX) Gets a Buy from Oppenheimer

Detailed price information for Gain Therapeutics Inc (GANX-Q) from The Globe and Mail including charting and trades.

1mo agoThe Globe and Mail

Also Discussed

Investors talking about GANX also mention

#	Name	Attention
1	Coya Therapeutics, Inc.COYA	0%new
2	Atomera IncATOM	0%+0
3	Annovis Bio, Inc.ANVS	0%0
4	Rein Therapeutics Inc.RNTX	0%0
5	Cue Biopharma, Inc.CUE	0%new
6	PolyPid Ltd.PYPD	0%new
7	Compass Therapeutics, Inc.CMPX	0%new
8	Os Therapies Inc.OSTX	0.1%+0.07
9	Orchestra BioMed Holdings, Inc.OBIO	0%0
10	EXAI - Exscientia plc	——

Gain Therapeutics, Inc.

Healthcare
Biotechnology

Gain Therapeutics, Inc. is a clinical-stage biotechnology company focused on discovering and developing allosteric small molecule therapies for difficult-to-treat diseases. Its current research centers on neurodegenerative disorders and other conditions linked to protein misfolding, with a particular emphasis on Parkinson’s disease and select rare genetic diseases. The company’s lead candidate, GT-02287, is being evaluated for Parkinson’s disease and is part of a broader pipeline aimed at addressing underlying disease mechanisms rather than only managing symptoms. Gain Therapeutics also uses its Magellan drug discovery platform to identify novel allosteric binding sites and design proprietary compounds with the potential to modulate protein function. Headquartered in Bethesda, Maryland, Gain Therapeutics operates as a specialized player in precision medicine and computational drug discovery within the biotechnology sector.

Website

Location

4800 Montgomery Lane

Bethesda, MD, 20814

United States

Social

What share of all stock conversation is about GANX?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0.04% +0.02	0.01% +0	0.01% 0	0.01% +0

Sep 29

The CFO of Gain Therapeutics, Inc. (GANX) is leaving the company, and his departure may be seen as a non-material change that could lead to a buying opportunity.
The company's Phase 2 study is expected to begin immediately, and some investors are optimistic about the potential for a "pretty healthy bounce back" in the stock price by the end of the week.
The CFO's departure may be related to an impending business partnership (BP) deal, which could have implications for the company's financial management and SEC filings.

Generated by AI

Sentiment

Of the messages about GANX that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	73.38% -10.23	79.32% -13.87	85.76% -0.63	88.02% -7.5
Bearish	26.62% +10.23	20.68% +13.87	14.24% +0.63	11.98% +7.5

Bullish· Sep 29

The recent change in executive team is considered non-material, and the company is expected to begin its Phase 2 study immediately, providing a catalyst for the stock.
The buying activity in ITM calls, with over 1,200 $2 calls purchased while others are panicking, suggests a strong sentiment among investors.
The stock has the potential to close in the green, and some investors are confident that the share price will recover, with one predicting a "dip then rip" scenario.

Bearish· Sep 29

The company's CFO and CMO may be leaving, which could negatively impact the company's performance.
The stock's price has collapsed after a significant number of calls were traded, indicating a lack of confidence in the company's prospects.
The company's management may be incompetent, with one user suggesting that the company's demise is likely due to poor leadership.

Generated by AI

Topics

Of the messages about GANX that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	100%	66.67%	72.78%	51.07%
Technical Analysis	0%	31.67%	24.05%	27.58%
Analysts	0%	0%	2.53%	16.81%
Earnings	0%	1.67%	0.63%	3.37%
Macro	0%	0%	0%	0.33%
Controversies	0%	0%	0%	0.84%

Jun 29

Gain Therapeutics, Inc. (GANX) received FDA clearance to advance GT-02287 into Phase 2 clinical development for Parkinson's disease.
The IND authorization clears the path for Phase 2 clinical development in the U.S., expected to begin in 3Q26.
Phase 1 data showed favorable safety and tolerability, and biomarker and clinical evidence of activity for GT-02287 in both healthy volunteers and people with Parkinson's disease.

Generated by AI

Community

Of the messages about GANX, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	86.23%	90.21%	92.47%	61.38%
Newcomers	13.77%	9.79%	7.53%	38.62%

Regulars· Sep 29

The market's reaction to the CFO's departure seems to be a mix of disappointment and opportunity, with some traders seeing it as a "head-fake" that could lead to a rally.
The potential start of Phase 2 clinical trials, either with or without a partner, is a topic of discussion, with some speculating that the market may react negatively again if the news is not presented transparently.
The company's pipeline of disease-modifying therapies, including a potential treatment for Parkinson's disease, is seen as a major advantage over competitors like Abbvie, with some traders speculating that the stock could be renamed in the future due to the potential for significant profits.

Newcomers· Feb 24

Newcomers are optimistic about Gain Therapeutics' GT-02287's potential to modify Parkinson's disease.
GT-02287's disease-modifying effects are a key focus for these newcomers, with some seeing it as a game-changer.
Some newcomers are holding onto GANX, expecting a continued upward trend based on GT-02287's potential.

Generated by AI

Gain Therapeutics

Social

Sep 29

Bullish· Sep 29

Bearish· Sep 29

Jun 29

Regulars· Sep 29

Newcomers· Feb 24

Gain Therapeutics announces CFO resignation and interim appointment

Gain Therapeutics to Participate at ROTH Fifth Annual Healthcare Opportunities Conference

H.C. Wainwright reiterates Gain Therapeutics stock rating at buy

Gain Therapeutics to Participate at H.C. Wainwright 28th Annual Global Investment Conference

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Gain Therapeutics (GANX), Summit Therapeutics (SMMT) and Elutia (ELUT)

Gain Therapeutics (GANX) Gets a Buy from Oppenheimer

Also Discussed

Gain Therapeutics, Inc.

Company Information

Location

Gain Therapeutics announces CFO resignation and interim appointment

Gain Therapeutics to Participate at ROTH Fifth Annual Healthcare Opportunities Conference

H.C. Wainwright reiterates Gain Therapeutics stock rating at buy

Gain Therapeutics to Participate at H.C. Wainwright 28th Annual Global Investment Conference

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Gain Therapeutics (GANX), Summit Therapeutics (SMMT) and Elutia (ELUT)

Gain Therapeutics (GANX) Gets a Buy from Oppenheimer

Also Discussed

Social

Sep 29

Bullish· Sep 29

Bearish· Sep 29

Jun 29

Regulars· Sep 29

Newcomers· Feb 24